Abstract
Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the GI tract with a new patient diagnosis of 4000–6000 per year in the USA. The pathological characterization of this tumor and the molecular basis of its treatment in the last several decades illustrate the complexity and beauty of targeted treatment for cancer.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Berthet B, Sugarbaker TA, Chang D, Sugarbaker PH. Quantitative methodologies for selection of patients with recurrent abdominopelvic sarcoma for treatment. Eur J Cancer. 1999;35:419–3.
Druker BJ, Lydon NB. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest. 2000;105:3–7.
Joensuu H, Roberts PJ, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with metastatic gastrointestinal stromal tumor. N Engl J Med. 2001;344:1052–6.
Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995;221:29–42.
Rutkowski P, Bylina E, Wozniak A, et al. Validation of the Joensuu risk criteria for primary resectable gastrointestinal tumor-the impact of tumor rupture on patient outcomes. Eur J Surg Oncol. 2011;37:890–6.
McCarter MD, Antonescu CR, Ballman KV, Maki RG, Pisters PW, Demetri GD, et al. Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence. J Am Coll Surg. 2012;215:53–9.
DeMatteo RP, Ballman KV, Antonescu CR, Corless C, Kolesnikova V, von Mehren M, et al. Long term results of adjuvant imatinib mesylate in localized, high risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (alliance) intergroup phase 2 trial. Ann Surg. 2013;258:422–9.
Corless CL, Ballman KV, Antonescu CR, Kolesnikova V, Maki RG, Pisters PW, et al. Pathologic and molecular features correlate with long term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial. J Clin Oncol. 2014;32:1563–70.
Agaimy A, Wunsch PH, Hofstaedter F, et al. Minute gastric sclerosing stromal tumors are common in adults and frequently show c-KIT mutations. Am J Surg Pathol. 2007;31:113–20.
Kawanowa K, Sakuma Y, Sakurai S, et al. High incidence of microscopic gastrointestinal stromal tumors in the stomach. Hum Pathol. 2006;37:1527–35.
Raut CP, Posner M, Desai J, Morgan JA, George S, Zahrieh D, et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol. 2006;24:2325–31.
Bamboat ZM, Dematteo RP. Metastasectomy for gastrointestinal stromal tumors. J Surg Oncol. 2014;109:23–7.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Steves, M. (2017). Specific Surgical Topics: Surgical Management of Gastrointestinal Stromal Tumors. In: Henshaw, R. (eds) Sarcoma. Springer, Cham. https://doi.org/10.1007/978-3-319-43121-5_8
Download citation
DOI: https://doi.org/10.1007/978-3-319-43121-5_8
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-43119-2
Online ISBN: 978-3-319-43121-5
eBook Packages: MedicineMedicine (R0)